SCHEMBL9403366

SCHEMBL9403366

ClC1CCc2cc(Br)cnc21

nearest known ligand 0.33

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
FNTA P49354 20/20 0.33
FNTB P49356 20/20 0.33
HRAS P01112 1/20 0.32
KRAS P01116 1/20 0.32
ABCB1 P08183 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18650419 0.79 AKR1B1 (0.34) FNTAFNTB
SCHEMBL30849376 0.78 OPRL1 (0.36)
SCHEMBL30702209 0.78 HTT (0.35) FNTAFNTBHRASKRASABCB1
SCHEMBL30856753 0.78 FNTA (0.33) FNTAFNTBHRASKRASABCB1
SCHEMBL14616893 0.78 HTT (0.35) FNTAFNTBHRASKRASABCB1
SCHEMBL14616897 0.78 FNTA (0.33) FNTAFNTBHRASKRASABCB1
SCHEMBL30702240 0.78 FNTA (0.33) FNTAFNTBHRASKRASABCB1
SCHEMBL17942179 0.73 MAP4K4 (0.35) FNTAFNTBHRASKRASABCB1
SCHEMBL21499843 0.72 FNTA (0.37) FNTAFNTBHRASKRASABCB1
SCHEMBL10287035 0.71 POLB (0.36) FNTAFNTBHRASKRASABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11845748-B2 Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors JANSSEN PHARMACEUTICA NV (BE) 2023-12-19 US disclosed
US-11814364-B2 Pyridine N-oxide derivatives useful as factor XIa inhibitors JANSSEN PHARMACEUTICA NV (BE) 2023-11-14 US disclosed
US-11814364-B2 Pyridine N-oxide derivatives useful as factor XIa inhibitors JANSSEN PHARMACEUTICA NV (BE) 2023-11-14 US disclosed
US-20220306632-A1 BICYCLIC PYRIDINE N-OXIDE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2022-09-29 US disclosed
WO-2017188288-A1 5-SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK ACTIVATION ACTION 塩野義製薬株式会社 2017-11-02 WO disclosed
US-5338740-A Angiotensin II receptor antagonists PFIZER INC. (US) 1994-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306632-A1 BICYCLIC PYRIDINE N-OXIDE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS F2, F11, KLKB1 FNTA 1448/4885FNTB 1477/4885HRAS 4027/4885
US-11845748-B2 Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors F2, F11, KLKB1 FNTA 1448/4885FNTB 1477/4885HRAS 4027/4885
US-11814364-B2 Pyridine N-oxide derivatives useful as factor XIa inhibitors F11, F2, KLKB1 FNTA 1126/4885FNTB 1470/4885HRAS 3798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.